Pelago Bioscience AB

Pelago Bioscience is excited to attend the American Association for Cancer Research Annual Meeting 2025, taking place April 25–30 in Chicago. Visit us at Booth #1656 to explore how CETSA® technology enables decision-making with biologically meaningful data across oncology and drug discovery programs. Whether screening for new hits, profiling selectivity, or working with challenging targets, CETSA clarifies compound-target interactions in intact cells. Our team will also present four scientific posters showcasing the application of CETSA across PROTAC development, high-throughput screening, mutant p53 research, and large-scale selectivity profiling. You'll find us represented at AACR by: R&D – Tomas Friman, Daniel Martinez Molina Project Advisors – Helena Almqvist Agata Habas, Julia Popp US Sales – Dan Campbell Stephen Kosteski, Brian W. J. CEO - Michael Dabrowski We look forward to connecting with oncology researchers, drug developers, and discovery teams throughout the week. Interested in setting up a meeting at the event? Book a time with us at AACR 2025: https://hubs.la/Q03dTw7Y0 More information about our participation: https://hubs.la/Q03dSZN90 #DrugDiscovery #protacs #CETSA #degraders #moleculartherapeutics

Drug discovery is tough enough. Are you using the right tools at the right time? Waiting too long to identify your drug’s targets or understand its mechanism can cost you valuable time and resources. Our latest blog reveals how applying proteome-wide CETSA® profiling early transforms your drug discovery process: - Uncover your compound’s true mechanism of action faster—directly in live, physiologically relevant environments. - Identify off-target liabilities early, reducing costly downstream risks. - Leverage unbiased, label-free target engagement data to accelerate confident decision-making. Real-world case studies—from novel cancer targets (PIP4K) to unexpected safety liabilities (FECH)—demonstrate clear, actionable insights and measurable impact. Ready to boost your pipeline’s efficiency and success rate? Read the blog here: https://hubs.la/Q03dQljh0 Want more detail and additional insights? Download our full e-book, "Right tools, right time." https://hubs.la/Q03dQlgm0

Pelago Bioscience is attending New Therapeutic Modalities: Transforming Receptor Pharmacology, organized by the British Pharmacological Society, on April 2–3 in Cambridge, UK. This event brings together researchers and industry experts to explore the latest advances in receptor pharmacology and new therapeutic approaches. If you are attending, meet our team to explore how CETSA can support your research. Mary Spanou(Regional Sales Manager) and Isabel M Caballero PharmD PhD (Project Advisor) are attending and are happy to discuss how CETSA® technology provides biologically relevant insights to accelerate drug discovery and development. Book a meeting here: https://hubs.la/Q03dgzQV0 Join Our Presentations Poster Presentation "Enhancing PROTAC research: CETSA as a tool for assessing selectivity of warheads and PROTACs and evaluation of non-degraded targets" Presenter: Isabel Martin Caballero Poster #13 April 2–3, during lunch and refreshment intervals Scientific Talk "CETSA-based evaluation of non-degraded PROTAC targets. Assessing degraders binding and MoA in live cells" Presenter: Isabel Martin Caballero April 2, 3:30–3:50 PM Visit our website for the details: https://hubs.la/Q03dgB4K0 #DrugDiscovery #CETSA #protacs #degraders

Ever wonder why so many promising drugs never make it to market? The surprising truth is that nearly half of drug candidates fail clinical trials because they simply can't engage effectively with their targets. Imagine pouring billions into developing a therapy only for it to miss the mark—literally. What's behind these missed opportunities? * Preclinical tests not predicting real-world outcomes * Drugs not reaching their intended targets in sufficient amounts * Misunderstood or overly complex target biology But there's good news! Emerging tools like CETSA® technology are transforming the way researchers validate and measure drug-target interactions, ensuring therapies hit their mark effectively: * Identify weak candidates early—before investing millions * Improve preclinical validation accuracy * Accelerate the move toward personalized medicine with robust biomarkers Curious how this breakthrough could transform your drug discovery efforts? Check out our latest blog and discover how CETSA® technology can help you deliver better therapies, faster. https://hubs.la/Q03cTXVP0 #DrugDiscovery #TargetEngagement #CETSA #PharmaInnovation #Biotechnology

Missed our live webinar? Now available on-demand. Discover how Sitryx leveraged CETSA® technology to enhance translational drug development in our exclusive webinar with Jonathan Ellery, Director of Biology at Sitryx. Gain insights into: How CETSA was applied in Sitryx’s drug discovery program The role of CETSA in validating in vivo target engagement A real-world case study on CETSA-driven decision-making in small molecule development Whether you work in early discovery or translational research, this session provides valuable insights into how CETSA can de-risk and accelerate your drug development pipeline. Watch the recording now: https://hubs.la/Q03cvr4p0 #TargetEngagement #CETSA #DrugDiscovery #invivo

New Blog Post: Your Drug Is in the Bloodstream—But Is It Actually Working? Getting a drug into the bloodstream is one thing. Proving it engages its target in real physiological conditions? That’s the real challenge. Traditional assays struggle with whole blood— complex composition, donor variability, and the need for reliable, scalable assays. So how can you be sure your drug is doing what it’s supposed to? In our latest blog, we explore how CETSA® technology changes the game. Unlike biochemical assays, CETSA provides direct, modification- free insights into drug-target interactions—helping researchers confidently track drug activity from discovery to clinical trials. In collaboration with AbbVie, we developed a scalable CETSA workflow that: ✅ Measures target engagement in fresh & frozen whole blood ✅ Tracks RIPK1 engagement using AlphaLISA™ and MSD® detection ✅ Adapts cell-based assays to whole blood for real clinical insights With biomarker-driven drug development on the rise, having a reliable target engagement assay isn’t just an advantage—it’s a necessity. Read the full article & download our application note: https://hubs.la/Q03bTTQF0 #CETSA #DrugDiscovery #TargetEngagement #ClinicalResearch #Biomarkers

Your target engagement data might be misleading you. And that could cost you millions in failed clinical trials. Traditional assays confirm binding— but does your drug actually engage its target in human blood? 90% of drug discovery efforts fail in clinical trials. One reason? Weak target engagement data that doesn’t translate in vivo. Developed in collaboration with AbbVie, CETSA® provides real-world target engagement proof—directly in whole blood. ✔️ Measures engagement in fresh & frozen blood samples ✔️ Overcomes high-abundance protein challenges (e.g., hemoglobin, albumin) ✔️ Ensures seamless sample transfer & clinical relevance Want to see the data for yourself? Download our app note: https://hubs.la/Q03bJtcp0 Read the full study: https://hubs.la/Q03bJSnK0 Smarter decisions start with the right data. With CETSA, you don’t assume—you know.

They changed science. The world tried to hold them back. Tomorrow is International Women’s Day, and we’re celebrating the brilliant women who reshaped medicine—even when the world wasn’t ready to celebrate them. 💡 Marie Curie carried radium in her pockets before we understood radiation risks. 💡 Rosalind Franklin’s work on DNA was used without her permission. 💡 Gerty Cori was demoted for years—just because she was a married woman. Some, like Tu Youyou, Katalin Karikó, and Jennifer Doudna, are still changing science today. Others never got the recognition they deserved. But every one of them refused to back down. Their breakthroughs were honored by the The Nobel Prize and Karolinska Institutet. Yet, there are still many women in science whose contributions remain uncelebrated. At Pelago Bioscience, we stand on the shoulders of pioneers like them. Science moves forward when bold thinkers challenge the status quo—just like these women did. Who else deserves recognition? Tag a scientist who inspires you! #InternationalWomensDay #WomenInScience #NobelPrize #STEM #DrugDiscovery

New Blog Post: Are Your Degraders Truly Working? In drug discovery, a degrader that binds but doesn’t degrade is a dead end. How can you separate functional degraders from silent binders? Targeted protein degraders—like PROTACs and molecular glue degraders—are transforming drug discovery by eliminating disease-driving proteins. But optimizing them for clinical success is no small feat. Key questions researchers must answer early on: - Is the degrader engaging the right target inside cells? - Is the degradation effect specific, or are off-target interactions occurring? - What SAR data defines potency and selectivity? - How can novel E3 ligases be identified? Traditional assays often fall short in providing physiologically relevant insights. That’s where CETSA® makes a difference. ✔ Confirm degrader-target engagement inside live cells ✔ Identify novel E3 ligases and understand degradation mechanisms ✔ Distinguish active degraders from silent binders ✔ Reduce off-target risks with unbiased proteome-wide profiling Pharma and biotech leaders are integrating CETSA into their degrader programs to enhance hit validation, optimize SAR analysis, and accelerate drug discovery. Read our latest blog to explore how CETSA is driving advancements in protein degrader research: https://hubs.la/Q039NcTX0

Join Us in London - ELRIG Research & Innovation 2025, March 10–11, a key event bringing scientists and industry leaders together to explore the latest drug discovery and development breakthroughs. Mary Spanou (Regional Sales Manager) and Isabel M Caballero PharmD PhD Martin Caballero (Project Advisor) are ready to discuss how CETSA® technology provides biologically relevant insights to accelerate decision-making in drug discovery. Poster Presentation "Enhancing PROTAC research: CETSA as a tool for assessing selectivity of warheads and PROTACs and evaluation of non-degraded targets" Presenter: Isabel Martin Caballer Location: Poster #22 Day 1 – March 10, 17:00–17:30 Day 2 – March 11, 13:30–14:00 Attending the conference? Meet us to explore how Pelago Bioscience can support your research. Book a meeting here: https://hubs.la/Q039pD2F0